Who is sponsoring NCT02138721?

NCT02138721 is sponsored by University Hospital, Ghent.

What drugs are being tested in NCT02138721?

Interventions in NCT02138721: Radical Prostatectomy (RP).

What condition does NCT02138721 study?

NCT02138721 studies Prostatic Neoplasms, Neoplasm Metastasis.

Is NCT02138721 still recruiting?

NCT02138721 is currently status unknown. Last updated 20 December 2023.

Last reviewed 2023-12-20 · How we verify

NCT02138721: LoMP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local Treatment With RP for Newly-diagnosed mPCa

Status unknown NA Last updated 20 December 2023

What this trial tests

NA trial testing Radical Prostatectomy (RP) in Prostatic Neoplasms in 80 participants. Status unknown.

Timeline

28 June 2018

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	University Hospital, Ghent
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	28 June 2018
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	5 locations across Belgium

Drugs / interventions tested

Radical Prostatectomy (RP)

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Neoplasm Metastasis — all drugs for Neoplasm Metastasis →

Sponsor

University Hospital, Ghent

Who can join

Adults 18 to 85, male only, with Prostatic Neoplasms or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the role of local treatment with radical prostatectomy in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
Lumen N, De Bleser E, Buelens S, Verla W, et al · · 2021 · cited 34× · PMID 34337536 · DOI 10.1016/j.euros.2021.05.006
Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.
Pizurica M, Larmuseau M, Van der Eecken K, de Schaetzen van Brienen L, et al · · 2023 · cited 20× · PMID 37352385 · DOI 10.1158/0008-5472.can-22-3113
Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
Buelens S, Poelaert F, Claeys T, De Bleser E, et al · · 2022 · cited 20× · PMID 34289231 · DOI 10.1111/bju.15553
Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
Koo KC, Dasgupta P. · · 2018 · cited 14× · PMID 29869454 · DOI 10.3349/ymj.2018.59.5.567
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.
Bianchini D, Lorente D, Rescigno P, Zafeiriou Z, et al · · 2017 · cited 13× · PMID 28571827 · DOI 10.1016/j.clgc.2017.04.013
Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review.
Mahjoub S, Heidenreich A. · · 2021 · cited 9× · PMID 34430419 · DOI 10.21037/tau-20-1033
Multifocal cohort analysis unveils cell types associated with regional lymph node seeding in prostate cancer.
de Schaetzen van Brienen L, Jung T, Larmuseau M, Van der Eecken K, et al · · 2026 · PMID 41787470 · DOI 10.1186/s13073-026-01616-y

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other University Hospital, Ghent trials

Trials by the same sponsor.

NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02138721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
Last refreshed: 20 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02138721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing